The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases

Journal of Medical Virology

Volumn 84, Issue 5, 2012, Pages 747-755

  Fabris, Carlo ^a   Falleti, Edmondo ^a   Cussigh, Annarosa ^a   Bitetto, Davide ^a   Fontanini, Elisabetta ^a   Colletta, Cosimo ^b   Vandelli, Carmen ^c   Cmet, Sara ^a   Ceriani, Elisa ^d   Smirne, Carlo ^d   Toniutto, Pierluigi ^a   Pirisi, Mario ^d  

^a UNIVERSITY OF UDINE   (Italy)

^b Madonna del Popolo Hospital   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Hepatitis C; Interleukin 28B; Serum cholesterol, staging; Transaminases

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 28B; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE COURSE; FATTY LIVER; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTEIN INTERACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL CLEARANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; CHILD; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TRANSAMINASES; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84858591719     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23259     Document Type: Article

References (42)

1. Afdhal NH. 2004. The natural history of hepatitis C. Semin Liver Dis 24: 3- 8.
2. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. 2004. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 36: 646- 654.
3. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006a. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501- 4509.
4. Ank N, West H, Paludan SR. 2006b. IFN-lambda: Novel antiviral cytokines. J Interferon Cytokine Res 26: 373- 379.
5. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. 2005. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86: 1589- 1596.
6. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. 2006. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 13: 297- 302.
7. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. 2009. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51: 655- 666.
8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. 1999. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467- 2474.
9. Cho O, Hong SH, Kim JS, Yoon JK, Kim K, Chwae YJ, Shin HJ, Park S. 2010. IFN-lambda endocytosis and IFN-lambda responsive promoter activation are dependent on cholesterol. Cytokine 51: 93- 100.
10. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. 2009. Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology 50: 1030- 1037.
11. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, Cmet S, Fornasiere E, Fumolo E, Fangazio S, Cerutti A, Minisini R, Pirisi M, Toniutto P. 2011. IL-28B rs12979860C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54: 716- 722.
12. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. 1997. Blood lipids of patients with chronic hepatitis: Differences related to viral etiology. Clin Chim Acta 261: 159- 165.
13. Feld JJ, Liang TJ. 2006. Hepatitis C - identifying patients with progressive liver injury. Hepatology 43: S194- S206.
14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399- 401.
15. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. 2010. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52: 864- 874.
16. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ. 2009. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 83: 3834- 3842.
17. Hui CK, Belaye T, Montegrande K, Wright TL. 2003. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38: 511- 517.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmannm BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22: 696- 699.
19. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. 2009. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 50: 729- 735.
20. Lawson A. 2010. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: Do they exist and is this really a group with mild disease? J Viral Hepat 17: 51- 58.
21. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. 2010. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51: 1904- 1911.
22. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, Degott C, Valla DC, Marcellin P. 2001. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34: 1000- 1005.
23. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. 2006. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 44: S19- S24.
24. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. 1998. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27: 868- 872.
25. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. 2010. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307- 2314.
26. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. 2005. Biological activity of interleukins-28 and -29: Comparison with type I interferons. Cytokine 31: 109- 118.
27. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, Nunez-Roldan A, Gonzalez-Escribano MF. 2010. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52: 33- 37.
28. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282: 7576- 7581.
29. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, Nicosia A, Vecchione R, Mura VL, Masarone M, Torella R. 2006. Hepatitis C virus carriers with persistently normal ALT levels: Biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 13: 290- 296.
30. Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxi A. 2008. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103: 1136- 1144.
31. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. 2001. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34: 730- 739.
32. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. 1997. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26: 1393- 1398.
33. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ. 2010. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52: 854- 863.
34. Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79: 3851- 3854.
35. Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH. 1992. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12: 1053- 1062.
36. Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C. 2006. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J Viral Hepat 13: 56- 61.
37. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798- 801.
38. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120- 129 e118.
39. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Gobel U, Capka E, Wiegand J, Schiefke I, Guthoff W, Grungreiff K, Konig I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J. 2010. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586- 1592 1592 e1581.
40. Uze G, Monneron D. 2007. IL-28 and IL-29: Newcomers to the interferon family. Biochimie 89: 729- 734.
41. Wasley A, Alter MJ. 2000. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 20: 1- 16.
42. Williams MJ, Lang-Lenton M. 2011. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 18: 17- 22.